PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 112 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,853 | -4.1% | 1,818 | +32.4% | 0.00% | 0.0% |
| Q2 2023 | $19,661 | +100.6% | 1,373 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $9,803 | -37.7% | 1,373 | -2.1% | 0.00% | 0.0% |
| Q4 2022 | $15,730 | +1.3% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $15,534 | +31.3% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $11,833 | -38.0% | 1,402 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $19,081 | -83.7% | 1,402 | -76.4% | 0.00% | -50.0% |
| Q4 2021 | $116,879 | -38.7% | 5,942 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $190,738 | -5.2% | 5,942 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $201,137 | +49.3% | 5,942 | +65.7% | 0.00% | +50.0% |
| Q1 2021 | $134,728 | +13.1% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $119,160 | -9.4% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $131,535 | +11.4% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $118,048 | +27.5% | 3,587 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $92,616 | – | 3,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 5,827,415 | $187,060,000 | 14.97% |
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $66,378,000 | 14.44% |
| Abingworth LLP | 1,203,135 | $38,512,000 | 8.74% |
| Penn Mutual Asset Management, LLC | 86,940 | $2,791,000 | 4.41% |
| GREAT POINT PARTNERS LLC | 220,863 | $7,090,000 | 1.65% |
| RA Capital Management | 3,115,008 | $99,992,000 | 1.39% |
| StepStone Group LP | 422,085 | $13,549,000 | 0.88% |
| Summit Rock Advisors, LP | 34,100 | $1,094,000 | 0.65% |
| Rhenman & Partners Asset Management AB | 186,210 | $5,977,000 | 0.42% |
| Eventide Asset Management | 600,000 | $19,260,000 | 0.25% |